Device therapy is a nonpharmacological approach that presents a crucial advancement for
managing patients with atrial fibrillation (AF) and heart failure with preserved ejection …

Heart failure with preserved ejection fraction (HFpEF) is present in nearly half of patients
with heart failure. The prevalence of heart failure with normal or near-normal ejection …

Background The data on the effects of the angiotensin receptor–neprilysin inhibitor (ARNI)
sacubitril‐valsartan (LCZ696) in chronic heart failure (CHF) patients with end‐stage renal …

Heart failure (HF) is the cause of impaired exercise capacity due to insufficient peripheral
blood flow. The development of natriuretic peptide (NP) through inhibition of the neprilysin …

The prevalence of heart failure with preserved ejection fraction (HFpEF) accounts for
approximately 50% of the total heart failure population, and with the aging of the population …

Heart failure with reduced ejection fraction (HFrEF) is a clinical syndrome characterized by
volume overload, impaired exercise capacity, and recurrent hospital admissions. A major …

Recent studies have focused on treating heart failure, primarily mitigating symptoms and
reducing the risk of mortality and other cardiovascular complications. A promising new …

Background and purpose Previous studies demonstrated that elevated brain natriuretic
peptide (BNP) level is associated with adverse clinical outcomes of acute cerebral infarction …

Nuclear factor erythroid 2-related factor 2 (Nrf2) is an important transcriptional regulator that
plays a protective role against various cardiovascular diseases. Omaveloxolone is a newly …

Background Heart failure (HF) in patients undergoing maintenance hemodialysis (MHD)
increases their hospitalization rates, mortality, and economic burden significantly. We aimed …